Lbt Innovations Limited (ASX:LBT)


right-arrow Created with Sketch. -0.005 (-4.55%)
MCAP $35.18M
Last trade 16.10pm 24/01/2022 20mins delayed

Latest Announcements

13/01/2022LBTLbt Innovations Limited
12/01/2022LBTLbt Innovations Limited
11/01/2022 Price SensitivePSLBTLbt Innovations Limited
04/01/2022LBTLbt Innovations Limited
04/01/2022LBTLbt Innovations Limited
04/01/2022 Price SensitivePSLBTLbt Innovations Limited
30/12/2021LBTLbt Innovations Limited
30/12/2021LBTLbt Innovations Limited

Company Overview

LBT Innovations Limited is an Australia-based medical technology company. The Company is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets. The Company's product pipeline includes The Automated Plate Assessment System for antimicrobial resistance (APAS-AMR), WoundVue, Biofilm, Automated Gram Stain Assessment and MicroStreak. The Company's Automated Plate Assessment System (APAS) Independence is a platform technology that automates culture-plate screening and interpretation. APAS Independence screens, interprets, and sorts these plates, overcoming the bottleneck in lab workflows and freeing up microbiologist's time. Its APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates.

LBT in the news

LBT Innovations (LBT) completes the acquisition of Clever Culture Systems (CCS) and…
LBT Innovations (LBT) signs a binding agreement with Hettich to acquire 50…
LBT Innovations (LBT) is granted FDA clearance for its culture plate reading…
LBT Innovations (LBT) 50 per cent owned joint venture company, Clever Culture…

Search Previous Announcements